

119TH CONGRESS
1ST SESSION

S. 2842

To amend the Public Health Service Act to provide for congenital
Cytomegalovirus screening of newborns.

IN THE SENATE OF THE UNITED STATES

SEPTEMBER 17 (legislative day, SEPTEMBER 16), 2025

Mr. BLUMENTHAL (for himself, Mr. MARSHALL, and Mr. KELLY) introduced
the following bill; which was read twice and referred to the Committee
on Health, Education, Labor, and Pensions

A BILL

To amend the Public Health Service Act to provide for
congenital Cytomegalovirus screening of newborns.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as “Stop CMV Act of 2025”.

5 **SEC. 2. SCREENING OF CONGENITAL CYTOMEGALOVIRUS.**

6 Part A of title XI of the Public Health Service Act
7 is amended by inserting after section 1116 (42 U.S.C.
8 300b–15) the following:

1 **“SEC. 1116A. SCREENING OF CONGENITAL**
 2 **CYTOMEGALOVIRUS.**

3 “(a) IN GENERAL.—Each hospital or other health
 4 care entity caring for infants who are 21 days or less of
 5 age (as designated by the Secretary) may administer, or
 6 cause to have administered, to every such infant in its care
 7 a test for congenital Cytomegalovirus in accordance with
 8 this section.

9 “(b) PROCESS.—

10 “(1) IN GENERAL.—In carrying out this sec-
 11 tion, the chief executive officer for health in each
 12 State may prescribe standards and procedures for
 13 the administration of testing under subsection (a),
 14 including recording the results of such tests, track-
 15 ing activities, conducting follow-up reviews, and car-
 16 rying out educational activities.

17 “(2) DISSEMINATION OF INFORMATION.—In
 18 carrying out this section, the chief executive officer
 19 for health in each State may prescribe standards
 20 and procedures setting forth the manner in which
 21 testing information is disseminated to a parent or
 22 guardian of the infant to be tested.

23 “(3) FAILURE TO PRESCRIBE.—If a State has
 24 not prescribed standards and procedures that are
 25 approved as provided for in paragraph (4) by the
 26 date that is 2 years after the date of enactment of

1 the Stop CMV Act of 2025, the Discretionary Advi-
 2 sory Committee on Heritable Disorders in Newborns
 3 and Children established under section 1111 (re-
 4 ferred to in this section as the ‘Advisory Com-
 5 mittee’) shall prescribe appropriate standards and
 6 procedures which may be implemented by such
 7 State.

8 “(4) REVIEW AND APPROVAL.—The standards
 9 and procedures prescribed under this subsection
 10 shall be subject to review and approval by the Advi-
 11 sory Committee. In reviewing or prescribing stand-
 12 ards and procedures as required under this sub-
 13 section, the Advisory Committee shall consider
 14 standards and procedures adopted in other States
 15 with respect to the screening of congenital
 16 Cytomegalovirus, the standards and procedures
 17 adopted in such State with respect to the screening
 18 of infants for other heritable diseases, and any sci-
 19 entific evidence the Advisory Committee considers
 20 relevant to provide for the screening of infants for
 21 congenital Cytomegalovirus.

22 “(c) GRANTS.—

23 “(1) HEALTH RESOURCES AND SERVICES AD-
 24 MINISTRATION.—

“(A) IN GENERAL.—The Secretary, acting through the Administrator of the Health Resources and Services Administration, shall award grants to States that prescribe standards and procedures in accordance with paragraphs (1) and (2), to be distributed by the States to entities described in subsection (a) to administer tests in accordance with that subsection.

“(B) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to carry out subparagraph (A) such sums as may be necessary for each of fiscal years 2026 and 2027.

“(2) CENTERS FOR DISEASE CONTROL AND PREVENTION.—

“(A) IN GENERAL.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award grants to, or enter into cooperative agreements with, States to provide technical assistance to State agencies or designated entities of States—

“(i) to develop, maintain, and improve data collection systems relating to congenital Cytomegalovirus; and

“(ii) to assist in the education and training of health care providers, patients, and the general public regarding the risk reduction or prevention, symptoms, diagnosis, and treatment of congenital Cytomegalovirus, including, as necessary, through the publication of scientific, evidence-based educational materials on internet webpages maintained by State agencies or designated entities of States.

“(B) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to carry out subparagraph (A) such sums as may be necessary for each of fiscal years 2026 and 2027.

“(3) NATIONAL INSTITUTES OF HEALTH.—

“(A) IN GENERAL.—The Director of the National Institutes of Health shall—

“(i) for the purposes of this section, establish a program, or expand existing programs, of research and development on the efficacy of new screening techniques and technology relating to congenital Cytomegalovirus, including clinical studies

of screening methods, studies on efficacy of
intervention, and related research; and

“(ii) establish a program, or expand
existing programs, of research and develop-
ment into congenital Cytomegalovirus
diagnostics, prevention, treatments includ-
ing public health awareness campaigns,
risk reduction, and vaccine development,
and cures or treatments (during pregnancy
and after birth).

“(B) FUNDING.—The Director of the Na-
tional Institutes of Health shall carry out sub-
paragraph (A) using amounts available to the
Director and not otherwise obligated.”.

SEC. 3. ADVISORY COMMITTEE ON HERITABLE DISORDERS
IN NEWBORNS AND CHILDREN.

Section 1111(b) of the Public Health Service Act (42
U.S.C. 300b–10(b)) is amended—

(1) in paragraph (7) by striking “and” after
the semicolon;

(2) by redesignating paragraph (8) as para-
graph (9); and

(3) by inserting after paragraph (7) the fol-
lowing:

- 1 “(8) carry out activities under section 1116A;
- 2 and”.

